ACME United Corp. Q2 2026: Revenue Rises 16% as My Medic Adds Top Line, but Earnings Pulse Tunes to Seasonality

Ticker: ACU | EPS: diluted earnings per share increases year over year, with six-months softness reflected in the bottom line. Earnings surprise and revenue forecast remain opaque due to limited guidance.

A Quarter of Growth, a Half-Year of Nuance

ACME United Corporation (NYSE American: ACU) reported its second-quarter 2026 results with net sales of $62.7 million, up 16% from $54.0 million in the year-ago period. The six-month tally showed net sales of $115.0 million, a 15% increase from $100.0 million a year earlier. The company notes that excluding the January 2026 acquisition of the My Medic assets, comparable three-month sales rose 8% and six-month sales rose 7%.

Net income for the quarter was $5.1 million, or $1.22 per diluted share (EPS), versus $4.8 million, or $1.16 per diluted share in the prior-year quarter—an increase of about 6% in net income and 5% in EPS. For the six months ended June 30, 2026, net income was $6.0 million, or $1.46 per diluted share, compared with $6.4 million, or $1.57 per diluted share in the same period last year. That six-month result reflects a roughly 6% drop in net income and a 7% decline in diluted EPS, driven by a softer first quarter even as overall sales advanced.

My Medic: Growth Driver, Seasonal Margin Taker

The My Medic business—acquired in January 2026 and sold directly to consumers—contributed to top-line growth but delivered only a modest impact on earnings in the second quarter and the first half of 2026. Management notes the direct-to-consumer, seasonal nature of My Medic’s business has historically driven profit in the fourth quarter, a pattern they expect to continue. In other words, the new brand is adding fuel to the engine, but the exhaust is still feeling the seasonality brake.

In practical terms, the acquisition helped the revenue line without a commensurate lift in earnings power yet, a dynamic investors will want to watch as the company cycles through My Medic’s peak profitability window later in the year.

Management Commentary and the Operational Arc

Chairman and CEO remarks emphasize that Q2 delivered record revenues and income from operations as the company expanded across geographies and product lines. The statement notes growth across the U.S. and abroad, signaling a diversified demand base that could cushion ACU from any one-market shock. However, the written narrative in the press release stops short of a formal revenue forecast or forward-looking earnings guidance, leaving readers to infer momentum from the trailing numbers rather than a stated plan.

Overall, the narrative remains constructive about the integration of My Medic and the trajectory of core products in the first aid space. The takeaway is one of resilient top-line growth with a nuanced earnings path that reflects the timing of acquisitions and seasonal consumer demand.

Implications for ACU and Sector Peers

For shareholders and analysts, the Q2 results deliver a tidy top-line progression but a more complex earnings story when viewed through the six-month lens. The absence of a formal EPS consensus and the lack of a revenue forecast mean reactions will hinge on qualitative signals—geographic expansion, product mix shifts, and the cadence of My Medic’s contribution through the year. In practice, this translates to a cautious optimism: growth is tangible, but the margin and earnings trajectory depend on how the My Medic integration matures and how Q3/Q4 seasonality unfolds.

Peers in consumer medical goods and first-aid segments may draw two inferences. First, acquisitions can lift the revenue line even when near-term earnings power is muted, particularly when the acquired brand taps a strong consumer channel. Second, seasonality remains a powerful determinant of profitability for direct-to-consumer lines. A sector-wide takeaway is that a clean beat on revenue may not translate into a commensurate uplift in EPS if the seasonal profit engine isn’t fully online yet.

What to Watch Next

Key questions for investors include: Will ACU provide a revenue forecast or an earnings trajectory in subsequent quarters to anchor expectations? How will My Medic’s seasonality shift as the brand scales, and will the company manage to convert top-line gains into durable EPS growth? The answers will likely influence how the stock trades against peers navigating the same consumer-facing, seasonal profit cycles.

In the meantime, the quarter’s headline figures suggest a tone of steady progress rather than dramatic re-rating. The stock’s reaction may hinge on whether markets interpret the six-month dip in EPS as a transitory consequence of first-quarter softness and integration costs, or as a signal of a more persistent earnings cadence tied to My Medic’s profitability timing.

Bottom Line and Context

ACME United Corporation posted Q2 2026 net sales of $62.7 million and diluted EPS of $1.22, with six-month results showing a higher press on revenue but a softer earnings cadence relative to the prior year. The My Medic acquisition adds a growth engine to the top line while injecting seasonality into earnings, underscoring a classic tension between revenue expansion and near-term profitability. The absence of a stated EPS consensus or revenue forecast means the market must parse this through the lens of execution more than guidance, and sector peers will be watching closely how the company translates qualified growth into durable earnings power.